Evaxion Biotech A/S

About Evaxion Biotech A/S

Evaxion Biotech is a pioneering TechBio company focused on decoding the human immune system to develop novel vaccines for cancer and infectious diseases using their AI-Immunology™ platform. Their mission is to address critical health challenges by leveraging AI for fast and effective vaccine target discovery, design, and development.

Products & Services

AI-Immunology™:A clinically validated AI platform for vaccine target discovery, design, and development, targeting cancer and infectious diseases.

Eden™:A component of the AI-Immunology™ platform, focused on specific vaccine target identification.

ObsERV™:A tool within AI-Immunology™ for observing and predicting immune responses for vaccine development.

Pioneer™:A part of AI-Immunology™ aimed at pioneering new vaccine solutions.

Raven™:An AI-Immunology™ module for advanced vaccine design and prediction.

EVX-01:A personalized peptide-based cancer vaccine for metastatic melanoma, currently in Phase 2 clinical development.

Specialties

AI-driven vaccine development Immunology Personalized cancer vaccines Infectious disease therapies Machine learning in healthcare

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Equity (ATM Offering and Warrant Exercise) T: - FT: Equity (ATM Offering and Warrant Exercise)	A: 7200000 MR: - FA: 7.2 million FAN: 7200000	D: 2025-10-30 FD: 2025-10-30	-
2	RT: Debt to Equity Conversion T: - FT: Debt to Equity Conversion	A: 4100000 MR: - FA: €3.5 million FAN: 4100000	D: 2025-07-11 FD: 2025-07-11	1 investors
3	RT: Public Offering T: - FT: Public Offering	A: 10800000 MR: - FA: $10.8 million FAN: 10800000	D: 2025-01-31 FD: 2025-01-31	3 investors
4	RT: Public Offering T: - FT: Public Offering	A: 10800000 MR: - FA: 10.8 million FAN: 10800000	D: 2025-01-30 FD: 2025-01-30	3 investors

Equity (ATM Offering and Warrant Exercise) Latest

2025-10-30

$7.2M

Debt to Equity Conversion 2025-07-11

$4.1M

Public Offering 2025-01-31

$10.8M

View 3 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

C

Christian Kanstrup

CEO

A

Andreas Holm Mattsson

Founder and Chief AI Officer

LinkedIn (Pro only)

B

Birgitte Rønø

Chief Scientific Officer

T

Thomas Schmidt

Chief Financial Officer

M

Marianne Søgaard

Chairman of the Board

L

Lars Staal Wegner

Board Member

View 6 more team members with Pro

Unlock Full Team Directory

Recent News